- Born:
- 1962, Seattle, Washington, U.S.
- Awards And Honors:
- Nobel Prize (2024)
David Baker
-
Who is David Baker?
David Baker (born in 1962) is an American biochemist and computational biologist celebrated for his innovative computerized methods in de novo protein design, creating proteins with entirely new functions. His work significantly advanced synthetic biology, leading to the development of novel drugs and proteins for industrial uses. Baker's development of Rosetta, a computational platform for predicting and designing protein structures, marked a significant breakthrough. In 2024, he was awarded the Nobel Prize in Chemistry (shared with Demis Hassabis and John M. Jumper) for his groundbreaking contributions to computational protein design. In addition to the Nobel Prize, Baker's honors include the Breakthrough Prize in Life Sciences (2021), the Wiley Prize in Biomedical Sciences (2022), and membership in the National Academy of Sciences (2006).
1 Britannica SourceCreated from Britannica articles using AI. AI can make mistakes, so verify using Britannica articles. -
What is biochemistry and what does a biochemist do?
Biochemistry explores the chemical substances and processes occurring in living organisms, investigating changes during their development and life. It utilizes techniques from analytical, organic, and physical chemistry to understand the chemistry of life. Biochemists study metabolic processes, enzyme functions, and the genetic apparatus of cells. Their investigations extend to chemical changes in disease, drug action, and various aspects of medicine, including nutrition, genetics, and agriculture.
David Baker (born 1962) is an American biochemist and computational biologist known for developing computerized methods for de novo protein design, creating proteins with entirely new functions. His work has propelled advances in synthetic biology, novel drugs, and industrial proteins. In 2024, he shared the Nobel Prize in Chemistry for breakthroughs in computational protein design.
3 Britannica SourcesCreated from Britannica articles using AI. AI can make mistakes, so verify using Britannica articles. -
What is computational biology?
Computational biology applies computer science to understand and model life's structures and processes, using algorithms to represent and simulate biological systems and interpret large-scale experimental data.
David Baker, an American biochemist and computational biologist born in 1962, is known for developing computerized methods for de novo protein design. His work has propelled advances in synthetic biology, novel drugs, and industrial proteins. Baker's revolutionary Rosetta platform predicts and designs protein structures using a Monte Carlo sampling algorithm, enabling the modeling of protein folding and the creation of new proteins with desired functions. In 2024, Baker was awarded the Nobel Prize in Chemistry for his work in computational protein design.
2 Britannica SourcesCreated from Britannica articles using AI. AI can make mistakes, so verify using Britannica articles. -
What are some major discoveries or inventions by David Baker?
David Baker is an American biochemist and computational biologist notable for his contributions to protein structure prediction and design, which have propelled advancements in synthetic biology, drug development, and industrial protein applications.
Baker's team developed Rosetta, a computational platform for predicting and designing protein structures using a Monte Carlo sampling algorithm. In 2003, Rosetta designed an entirely new protein structure and computed a corresponding sequence of 93 amino acids. The researchers verified Rosetta’s output by inserting the gene for the novel sequence into bacterial cells, which then produced the artificial protein, known as Top7. Top7 was the first protein to be designed and produced de novo. Baker released Rosetta’s code, enabling the creation of novel proteins with valuable functions, such as enzymes for breaking down toxic chemicals and mini-proteins for therapeutic uses, including one inhibiting SARS-CoV-2.
1 Britannica SourceCreated from Britannica articles using AI. AI can make mistakes, so verify using Britannica articles. -
How does David Baker use computers to study proteins?
David Baker uses computers to study proteins by employing computational modeling to gain insight into the three-dimensional shapes resulting from protein folding and their relevance to protein function. This work led to his development of Rosetta, a computational platform that predicts and designs protein structures based on a Monte Carlo sampling algorithm.
Baker's team used Rosetta to predict how a given sequence would fold and later used it in reverse to obtain information on amino acid sequences based on a given protein structure, which allowed them to design proteins according to desired shapes. In 2003, Rosetta computed a sequence of 93 amino acids for an entirely new protein structure. The resulting artificial protein, Top7, was the first to be designed and produced de novo.
1 Britannica SourceCreated from Britannica articles using AI. AI can make mistakes, so verify using Britannica articles. -
Why is David Baker's work in protein design important for science and medicine?
David Baker's work in protein design is significant for science and medicine because he developed computerized methods for de novo protein design, creating proteins with entirely new functions. His revolutionary computational platform, Rosetta, allows researchers to model protein folding and design novel proteins with desired functions.
Baker's work has led to advances in synthetic biology, novel drug development, and industrial applications. For example, he created mini-proteins for therapeutic uses, including one that inhibits SARS-CoV-2. His research provides insights into protein structure-function relationships, useful for studying diseases and designing pharmaceuticals. In 2024, Baker, along with Demis Hassabis and John M. Jumper, was awarded the Nobel Prize in Chemistry for his breakthroughs in computational protein design.
3 Britannica SourcesCreated from Britannica articles using AI. AI can make mistakes, so verify using Britannica articles.
David Baker (born 1962, Seattle, Washington, U.S.) is an American biochemist and computational biologist who developed computerized methods for the de novo (from scratch) design of proteins with entirely new functions. Baker’s work on protein structure prediction and design fueled advances in synthetic biology and in the development of novel drugs and proteins for industrial applications. He was awarded the 2024 Nobel Prize in Chemistry (shared with English computer scientist Demis Hassabis and American researcher John M. Jumper) for his breakthroughs in computational protein design.
Education and early career
Baker grew up in Seattle. As an undergraduate, he attended Harvard University, where he studied philosophy and social science until his last year, when he transitioned to biology. After earning a bachelor’s degree from Harvard in 1984, he went to the University of California, Berkeley, to study biochemistry. There he carried out research on systems of protein transport in yeast. He earned a Ph.D. in 1989 and subsequently became a postdoctoral researcher at the University of California, San Francisco, where his focus shifted to structural biology. In 1993 he joined the faculty at the University of Washington and began to more deeply investigate protein folding and the ways in which sequences of amino acids form the wide variety of protein shapes observed in cells.
Rosetta
In the early 1990s Baker’s research team employed standard approaches available for protein analysis, including mass spectrometry and nuclear magnetic resonance spectroscopy. Eventually, however, they broadened their investigations to include computer modeling, which provided critical insight into the three-dimensional shapes that result from protein folding and the relevance of these shapes to protein function. This work led to his development of Rosetta, a revolutionary computational platform for predicting and designing protein structures that is based on a Monte Carlo sampling algorithm. Rosetta allows researchers to model protein folding and to design new proteins with desired functions.
In 1998 Baker used Rosetta in a competition known as Critical Assessment of protein Structure Prediction (CASP), a biennial scientific experiment in which participants attempt to predict the structures of proteins from known amino acids sequences. Rosetta performed well in the competition, successfully predicting how a given sequence would fold. After a series of refinements, Baker’s team began using Rosetta in reverse, obtaining information on amino acid sequences based on a given protein structure. In this way, researchers gained the ability to design proteins according to desired shapes.
Baker’s major breakthrough came in 2003, when Rosetta was fed an entirely new protein structure and computed a corresponding sequence consisting of 93 amino acids. The researchers verified Rosetta’s output by inserting the gene for the novel sequence into bacterial cells, which then produced the artificial protein, known as Top7. Top7 was the first protein to be designed and produced de novo. Baker subsequently released Rosetta’s code, making it available to other researchers. The technology has enabled Baker and others to create novel proteins with valuable functions, such as enzymes that specialize in breaking down toxic chemicals. Baker has also developed mini-proteins for therapeutic applications, including a mini-protein of about 56 amino acids capable of inhibiting SARS-CoV-2, the virus responsible for the COVID-19 pandemic.
Awards and honors
Baker has received various awards throughout his career, in addition to the Nobel Prize. In 2002 he was awarded the Overton Prize by the International Society for Computational Biology, and in 2004 he received the Feynman Prize in nanotechnology from the Foresight Institute (shared with Brian Kuhlman). In 2021 he was recognized with the prestigious Breakthrough Prize in Life Sciences and the following year received the Wiley Prize in Biomedical Sciences (shared with Hassabis and Jumper). He is a Howard Hughes Medical Institute investigator (2000) and a member of the National Academy of Sciences (2006).